R&D News | pharmaphorum

News

A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.

News

Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.

News

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.

News

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

News

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.